EMA Boosts Transparency On Maintaining Orphan Status At Time Of Approval
Executive Summary
New orphan maintenance assessment reports are expected to increase transparency around the European Medicines Agency's decision-making process on whether an orphan-designated drug continues to qualify as an orphan once it gets on to the market.
You may also be interested in...
Orphan Drugs Study Compares EMA's Significant Benefit With HTA's Relative Effectiveness Assessments
A first of its kind study is underway to look at how the significant benefit assessment of orphan products by the European Medicines Agency compares with relative effectiveness assessments by health technology assessment bodies.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.